What retatrutide's win means for the GLP-1 market
BioReview argues the trial puts pressure on Novo Nordisk, whose own triple-acting candidates are still in Phase 2, and highlights analyst forecasts of multi-billion-dollar peak sales for retatrutide.
Source: BioReview (2 Nov 2026).